Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX 1416 in Postbariatric Hypoglycemia (STEADI)
NCT07029412Phase 2Completed
- Sponsor
- MBX Biosciences, Inc.
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of imapextide in post-bariatric hypoglycemia (PBH), sponsored by MBX Biosciences, Inc.. Started Aug 2025; status: completed.
02
Drugs
imapextide
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT07029412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029412.